Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, 5-17 years of age~* Subjects must have a DSM-IV diagnosis of a bipolar spectrum disorder (type I, II, or Not Otherwise Specified) and currently display mixed, manic, or hypomanic symptoms (without psychotic features) according to clinical assessment based on the DSM-IV and confirmed with structured diagnostic interview~* Subjects and their legal representative must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator and to cooperate with all tests and examinations required by the protocol~* Subjects and their legal representatives must be considered reliable.~* Each subject and his/her authorized legal representative must understand the nature of the study. The subject's authorized legal representative must provide written consent and the subject must provide written assent.~* Subjects must have an initial score on the YMRS of at least 15.~Exclusion Criteria:~* Investigator and his/her immediate family (defined as the investigator's spouse, parent, child, grandparent, or grandchild)~* Serious or unstable illness including hepatic, rental, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease~* Uncorrected hypothyroidism or hyperthyroidism~* History of sensitivity to N-acetylcysteine, a history of intolerance to N-acetylcysteine, or a non-responder after 2 months of treatment at adequate doses as determined by the clinician~* Severe allergies or multiple adverse drug reactions~* Current or past history of seizures~* Active substance abusers, per clinician judgment~* Judged clinically to be at serious suicidal risk~* Current diagnosis of schizophrenia~* Pregnancy~* C-SSRS score ≥ 4~* IQ \< 70

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Open-label Treatment with NAC (Type: EXPERIMENTAL): 12-week, open-label treatment with NAC. Subjects will be treated with the following dose:~Subjects ages 5-12:~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM~Subjects ages 13-17:~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence.

Based on this trial design, predict the completion outcome and termination type (if applicable).